Inhibikase Therapeutics, Inc. Stock Issued During Period, Shares, Restricted Stock Award, Forfeited
Inhibikase Therapeutics, Inc. (IKT) had Stock Issued During Period, Shares, Restricted Stock Award, Forfeited of 40.00 thousand shares as of 2022-09-01, per its 10-Q filed 2022-11-14.
Discontinued › Shareholders' Equity
us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited · last filed 2022-11-14
- 2022-09-01: Stock Issued During Period, Shares, Restricted Stock Award, Forfeited 40.00K shares.
| Period end | Stock Issued During Period, Shares, Restricted Stock Award, Forfeited |
|---|---|
| 2022-09-01 | 40.00K shares 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |